These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17251189)

  • 1. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration.
    Garcia-Saez I; DeBonis S; Lopez R; Trucco F; Rousseau B; Thuéry P; Kozielski F
    J Biol Chem; 2007 Mar; 282(13):9740-9747. PubMed ID: 17251189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
    Kaan HY; Ulaganathan V; Rath O; Prokopcová H; Dallinger D; Kappe CO; Kozielski F
    J Med Chem; 2010 Aug; 53(15):5676-83. PubMed ID: 20597485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.
    Maliga Z; Kapoor TM; Mitchison TJ
    Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New chemical tools for investigating human mitotic kinesin Eg5.
    Klein E; DeBonis S; Thiede B; Skoufias DA; Kozielski F; Lebeau L
    Bioorg Med Chem; 2007 Oct; 15(19):6474-88. PubMed ID: 17587586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
    DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
    Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monastrol inhibition of the mitotic kinesin Eg5.
    Cochran JC; Gatial JE; Kapoor TM; Gilbert SP
    J Biol Chem; 2005 Apr; 280(13):12658-67. PubMed ID: 15665380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
    Peters T; Lindenmaier H; Haefeli WE; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):291-9. PubMed ID: 16365780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
    Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
    J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
    Chin GM; Herbst R
    Mol Cancer Ther; 2006 Oct; 5(10):2580-91. PubMed ID: 17041103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition.
    Luo L; Carson JD; Dhanak D; Jackson JR; Huang PS; Lee Y; Sakowicz R; Copeland RA
    Biochemistry; 2004 Dec; 43(48):15258-66. PubMed ID: 15568818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5.
    Kapoor TM; Mayer TU; Coughlin ML; Mitchison TJ
    J Cell Biol; 2000 Sep; 150(5):975-88. PubMed ID: 10973989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
    Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
    Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
    Garcia-Saez I; Skoufias DA
    Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
    Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
    Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A structural model for monastrol inhibition of dimeric kinesin Eg5.
    Krzysiak TC; Wendt T; Sproul LR; Tittmann P; Gross H; Gilbert SP; Hoenger A
    EMBO J; 2006 May; 25(10):2263-73. PubMed ID: 16642039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioisosteric approach in designing new monastrol derivatives: an investigation on their ADMET prediction using in silico derived parameters.
    Hassan SF; Rashid U; Ansari FL; Ul-Haq Z
    J Mol Graph Model; 2013 Sep; 45():202-10. PubMed ID: 24080467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of MAC1: A Small Molecule That Rescues Spindle Bipolarity in Monastrol-Treated Cells.
    Al-Obaidi N; Mitchison TJ; Crews CM; Mayer TU
    ACS Chem Biol; 2016 Jun; 11(6):1544-51. PubMed ID: 27121275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pathway of structural changes produced by monastrol binding to Eg5.
    Maliga Z; Xing J; Cheung H; Juszczak LJ; Friedman JM; Rosenfeld SS
    J Biol Chem; 2006 Mar; 281(12):7977-82. PubMed ID: 16434397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.
    Müller C; Gross D; Sarli V; Gartner M; Giannis A; Bernhardt G; Buschauer A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):157-64. PubMed ID: 16703323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
    Tcherniuk S; van Lis R; Kozielski F; Skoufias DA
    Biochem Pharmacol; 2010 Mar; 79(6):864-72. PubMed ID: 19896928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.